The news is directly about Maravai LifeSciences. Goldman Sachs' decision to maintain a Neutral rating indicates that they do not expect significant price movement in the short term. However, the lowering of the price target could potentially have a negative impact, as it suggests that the analyst believes the stock is currently overvalued.